Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7954191 | 0.93 | TGFBR1 (0.48) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL27146439 | 0.90 | GPR119 (0.53) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL27141625 | 0.88 | GPR119 (0.59) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL4686828 | 0.87 | KDM4E (0.58) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL3949538 | 0.85 | STS (0.44) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL3949543 | 0.85 | STS (0.44) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL3949547 | 0.85 | STS (0.44) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL216692 | 0.84 | GPR119 (0.58) | KDM4EPKMGPR119STS | |
| SCHEMBL28504246 | 0.84 | STS (0.47) | TGFBR1KDM4EPKMGPR119STS | |
| SCHEMBL7667825 | 0.83 | NR1H2 (0.41) | TGFBR1KDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513253-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1465861-B1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1465861-A4 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1465861-A1 | ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003053912-A1 | α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | TGFBR1 2653/4885KDM4E 3469/4885PKM 1674/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | TGFBR1 1745/4885KDM4E 4714/4885PKM 3553/4885 |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | APP, APBA1, BACE1 | TGFBR1 1745/4885KDM4E 4714/4885PKM 3553/4885 |
| US-20040127494-A1 | Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors | APBA1, APP, BACE1 | TGFBR1 2425/4885KDM4E 4746/4885PKM 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.